Curative radiation therapy in prostate cancer

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 98-103

  Harmenberg, Ulrika ^a   Hamdy, Freddie C ^b   Widmark, Anders ^c   Lennernä, Bo ^d   Nilsson, Sten ^a,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UMEÅ UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Curative radiation therapy the rationale for dose escalation choice of radiation boost techniques

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANTIANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CAUSE SPECIFIC SURVIVAL; COMPARATIVE EFFECTIVENESS; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH DOSE RATE BRACHYTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; SALVAGE THERAPY; TREATMENT DURATION;

BRACHYTHERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79957510301     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.576115     Document Type: Article

References (43)

1. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405-18.
2. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, et al. Predicting prostate specifi c antigen outcome preoperatively in the prostate specifi c antigen era. J Urol 2001;166:2185-8. (Pubitemid 33065253)
3. Crook JM, Malone S, Perry G, Eapen L, Owen J, Robertson S, et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial. Cancer 2009;115:673-9.
4. Ljung G, Egevad L, Norberg M, Holmberg L, Nilsson S, Busch C. Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy. Prostate 1997;32:99-105. (Pubitemid 27280353)
5. Ljung G, Norberg M, Hansson H, de la Torre M, Egevad L, Holmberg L, et al. Transrectal ultrasonically-guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy. Acta Oncol 1995; 34:945-52.
6. Ljung G, Norberg M, Holmberg L, Busch C, Nilsson S. Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specifi c antigen, prostatic acid phosphatase, and cytokeratin 8. Prostate 1997;31: 91-7. (Pubitemid 27188137)
7. Almroth A, Ljung G, Eklund T, Nordgren H, Kalafatidis D, Ringqvist I, et al. Value of sextant biopsies in the assessment of local cure following external beam radiotherapy of prostatic adenocarcinoma. Scand J Urol Nephrol 1998;32:111-5. (Pubitemid 28206803)
8. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005; 44:265-76. (Pubitemid 40904130)
9. Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using highdose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002;52:81-90. (Pubitemid 34044108)
10. Vargas CE, Martinez AA, Boike TP, Spencer W, Goldstein N, Gustafson GS, et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 2006; 66:416-23. (Pubitemid 44332728)
11. Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 2005;47:441-8. (Pubitemid 40357885)
12. Kalkner KM, Wahlgren T, Ryberg M, Cohn-Cedermark G, Castellanos E, Zimmerman R, et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up. Acta Oncol 2007;46:909-17. (Pubitemid 47537169)
13. Guix B, Bartrina JM, Henriquez I. Dose escalation by combined treatment 3D-conformal radiotherapy plus HDR brachytherapy as treatment for intermediate-or high-risk cancer: Early toxicity and biochemical outcome of a prospective randomized trial. Radiother Oncol 2007;83:S39 [abstract 81].
14. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol 2007;84:114-20. (Pubitemid 47284526)
15. Pieters BR, de Back DZ, Koning CC, Zwinderman AH. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: A systematic review. Radiother Oncol 2009; 93:168-73.
16. Gottschalk AR, Roach M, 3rd. The use of hormonal therapy with radiotherapy for prostate cancer: Analysis of prospective randomised trials. Br J Cancer 2004;90:950-4. (Pubitemid 38495810)
17. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9-17.
18. Galalae RM, Martinez A, Nuernberg N, Edmundson G, Gustafson G, Gonzalez J, et al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose benefi cial in all prognostic risk groups? Strahlenther Onkol 2006;182:135-41.
19. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer signifi cantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. J Urol 2009;181:956-62.
20. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485):572-8. (Pubitemid 41140332)
21. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specifi c antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924-30.
22. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41. (Pubitemid 46972788)
23. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3): An open randomised phase III trial. Lancet 2009;373(9660):301-8.
24. Ordon M, Nam RK. Lymph node assessment and lymphadenectomy in prostate cancer. J Surg Oncol 2009;99: 215-24.
25. Yu CX, Tang G. Intensity-modulated arc therapy: Principles, technologies and clinical implementation. Phys Med Biol 2011;56:R31-54.
26. Nguyen PL, D'Amico AV. Targeting pelvic lymph nodes in men with intermediate-and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol 2008;26:2055-6; author reply 2056-7.
27. Roach M, 3rd. Targeting pelvic lymph nodes in men with intermediate-and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol 2008;26:3816-7; author reply 3817-8.
28. Wang D, Lawton C. Pelvic lymph node irradiation for prostate cancer: Who, why, and when? Semin Radiat Oncol 2008;18:35-40. (Pubitemid 350235954)
29. Kim BS, Lashkari A, Vongtama R, Lee SP, Parker RG. Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy. Clin Prostate Cancer 2004;3:93-7. (Pubitemid 39403227)
30. Williams SG, Taylor JM, Liu N, Tra Y, Duchesne GM, Kestin LL, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007;68: 24-33. (Pubitemid 46589844)
31. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11-8.
32. Lennernas B, Nilsson S, Levitt SH. Hypofractionation for radiotherapy of prostate cancer using a low alpha/beta ratio-possible reasons for concerns? An example of fi ve-dimensional radiotherapy. Acta Oncol 2011.
33. Miles EF, Lee WR. Hypofractionation for prostate cancer: A critical review. Semin Radiat Oncol 2008;18:41-7. (Pubitemid 350235955)
34. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies. Eur J Cancer 2010;46:3095-101.
35. Ljung G, Egevad L, Norberg M, de la Torre M, Holmberg L, Busch C, et al. Assessment of proliferation indicators in residual prostatic adenocarcinoma cells after radical external beam radiotherapy. Prostate 1996;29:303-10. (Pubitemid 26372603)
36. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105. (Pubitemid 34787842)
37. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr., Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294:1233-9. (Pubitemid 41352111)
38. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87. (Pubitemid 46805903)
39. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6. (Pubitemid 46622106)
40. Vance W, Tucker SL, de Crevoisier R, Kuban DA, Cheung MR. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys 2007;67: 828-33. (Pubitemid 46215871)
41. Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A. Infl uence of local tumor control on distant metastases and cancerrelated mortality after external beam radio therapy for prostate cancer. J Urol 2008;179:1368-73; discussion 1373.
42. Coquard R. Re: Infl uence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer: Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A. J Urol 2008;179:1368-73. J Urol 2008;180:2258; author reply 2258.
43. Solberg A, Haugen OA, Viset T, Bergh A, Tasdemir I, Ahlgren G, et al. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: A side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys.